ACT wins FDA OK for second stem cell trial
This article was originally published in Scrip
Advanced Cell Technology started 2011 off with a bang, with shares of the US biotech gaining as much as 25% in over-the-counter trading 3 January after it revealed that the US FDA gave the all clear for the firm to start the first ever clinical trial of an investigational human embryonic stem cell (hESC) therapy in patients with dry age-related macular degeneration (AMD).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.